


# Financial Statements

## Integrated Medical Solutions Limited

For the financial year ended 31 December 2019

COMPANIES HOUSE  
BELFAST  
15 APR 2021  
RECEPTION DESK

THURSDAY



\*JA2FRZR7\*  
JNI 15/04/2021 #49  
COMPANIES HOUSE

Registered number: 03037895

**Integrated Medical Solutions Limited**

## Contents

	Page
<b>Company information</b>	1
<b>Strategic report</b>	2
<b>Directors' report</b>	6 - 7
<b>Directors' responsibilities statement</b>	8
<b>Independent auditor's report</b>	9 - 12
<b>Statement of comprehensive income</b>	13
<b>Balance sheet</b>	14
<b>Statement of changes in equity</b>	15
<b>Notes to the financial statements</b>	16 - 30
<p>The following pages do not form part of the statutory financial statements:</p>	
<b>Detailed profit and loss account and summaries</b>	31 - 33

**Integrated Medical Solutions Limited**

## Company Information

<b>Directors</b>	Brian Timmons Shane Tickell (resigned 31 December 2019) Terence John Fossey (resigned 24 May 2019) Leesa Ewing (resigned 31 August 2019)
<b>Company secretary</b>	Ultan McGrath
<b>Registered number</b>	03037895
<b>Registered office</b>	Saxon Court 502 Avebury Boulevard Milton Keynes Buckinghamshire MK9 3GD
<b>Independent auditor</b>	Grant Thornton Chartered Accountants & Statutory Auditors 13-18 City Quay Dublin 2
<b>Bankers</b>	National Westminster 501 Silbury Boulevard Saxon Gate East Milton Keynes Bucks MK9 3ER United Kingdom
<b>Solicitors</b>	OBH Partners 17 Pembroke Street Upper Dublin 2 Ireland

## **Integrated Medical Solutions Limited**

# Strategic report

For the financial year ended 31 December 2019

### **Principal activities**

The principal activity of the Company is the development, marketing, sale and servicing of its web based, end to end, IMS MAXIMS electronic patient record system, a suite of clinical IT solutions and administrative applications suitable for any clinical specialism, to health care providers operating under the National Health Service (NHS), its major market, and across the Independent and private sector organisations market, ranging from hospitals groups to small specialist clinics.

### **Business review**

IMS MAXIMS enables healthcare organisations to achieve global digital excellence and in turn, safer, more effective, sustained healthcare. Our Global Digital Exemplar solutions (patient administration system, electronic patient record and suite of mobile applications) are designed in collaboration with clinicians over the last 30 years and are flexible enough to support a modular or holistic approach to digital. MAXIMS is used widely in the NHS, HSE, independent and private sectors. MAXIMS enables healthcare organisations to achieve digital excellence and in turn, safer, more effective, sustained healthcare

The group has in recent years has deployed and extended the MAXIMS platform for the provision of integrated EPR/PAS deployments in the Global Digital Exemplar (GDE) and Fast Follower designated Trusts, Somerset NHS Foundation Trust, and Wye Valley NHS Trust, and, in the private sector, in Ramsay Health UK. Hospital organisations that utilise IMS MAXIMS solutions also include Blackpool Teaching Hospitals NHS Foundation Trust, the BMI Hospitals (General Healthcare Group), Royal Cornwall Hospital Trust, St. Vincent's Hospital, University Hospital Limerick, Bon Secours, InHealth and Care UK.

In the course of the year the Company continued the development of its MAXIMS platform for service delivery and has developed and deployed a number of mobile apps (including e-Obs, Whiteboards, Hospital@Night, Theatre Aware) which have received very positive feedback from our customers. The market has a massive need for solutions that reduce the burden on clinicians and staff so that they can focus on patients. NHSX strategic goals include ensuring clinical information can be safely accessed wherever it is needed by providing healthcare professions the tools to access information and services directly - this offers great potential to vendors, such as ourselves, offering innovative, clinician led solutions. Our latest MAXIMS solutions and product strategy rethink how clinicians will interact with the MAXIMS Platform by providing a more seamless and instinctive user experience (mobile applications). We have reimagined a MAXIMS platform that will focus on harnessing data to drive operational and clinical efficiencies across healthcare settings. Our solutions are now designed to be part of a wider framework that focus on prevention, supports population health outcomes and support integrated health and care systems (supporting the growing number of patients with multiple-long term conditions that require several care services).

The UK market, is challenged by NHS funding issues arising from increasing demand pressures on the healthcare system, exacerbated by the impact of an ageing population, NHS reorganisation, and the ongoing political uncertainty from the Brexit Referendum and its aftermath, and the UK elections. Many NHS providers and commissioners ran significant deficits in their budgets for the last several years and leaving the NHS facing a major or severe funding problem.

## Integrated Medical Solutions Limited

# Strategic report (continued)

For the financial year ended 31 December 2019

### Principal risks and uncertainties

The directors consider that the principal risks and uncertainties faced by the company are in the following categories:

#### Market

The Company is exposed to market risk. While a significant level of the groups revenues are of a recurring nature, the prosperity and development of the group, and the company, is highly reliant on the closing of new contracts, primarily from the NHS but in the private market also. In order to mitigate this risk, the Company is assiduous in developing the products, the deployment methodology enabling the roll-out of its systems, and its relationships with key decisionmakers in the market, so as to ensure that its platform is pertinent to the needs of the healthcare market and profitably deliverable at an economic competitive price.

#### Economic

The company is exposed to the risk of foreign exchange losses, increased interest rates and or inflation having an adverse impact on served markets.

#### Competitor

The directors of the company manage competition through close attention to market research, benchmarking with competition, and recruitment of highly skilled professional staff.

#### Financial

The company prepares regular cash flow forecasts to review liquidity requirements, and has prepared detailed plans covering the next 12 months of trading. The plan is updated on a regular basis as and when new information becomes available. The directors have financial reporting procedures to manage credit, liquidity and other financial risk.

### Financial key performance indicators

The Company is a wholly owned subsidiary of Irish Medical Systems (Holdings) Ltd. (Holdings). The 2019 KPIs for the Company and the consolidated Holdings company were as follows:

	Company		Holdings	
	2019	2018	2019	2018
Turnover	£4.9m	£5m	€7.0m	€7.0m
EBITDA	(£0.3m)	(£1.9m)	€0.8m	(€0.7m)
Pretax loss	(£1.1m)	(£3.0m)	(€2.1m)	(€3.3m)
Net (liabilities)/assets	(£6.7m)	(£5.6m)	€9.2m	€8.1m

The Directors note the results of the group during the year, which reflect the significant upfront investment undertaken in recent years to extend the breadth and depth of the MAXIMS platform. The Company continues to enjoy the committed backing and financial support of its shareholder and Principal.

### Research and development

The group parent, Holdings, continues to invest heavily, c. €3.1million pa, in its unified domain platform from which its product suite is delivered. The group is a pioneer of open standards in the deployment of IT EPR systems, in association with the NHS and HSE, with a view to making available to clinicians and other health care professionals, the most cost effective, robust, interoperable, intuitive IT solutions.

## Strategic report (continued)

For the financial year ended 31 December 2019

### **Research and development (continued)**

Arising from the continued significant investment in its platform, and the incorporation of significant input from clinical and administrative users in the design process, the IMS MAXIMS suite of clinical and administrative software products is highly regarded throughout the UK and Irish healthcare sectors. Our range extends from large-scale systems to administer patient services across entire hospitals or trusts to specialised packages for tasks such as bed management or pathology and radiology order communications. MAXIMS products are highly functional and scalable, using robust and proven technology, and have been developed with clinical input to guarantee user-friendliness and clinical effectiveness.

It is our view that the next generation and era of Digital Healthcare should shift the focus onto how patient data is leveraged to improve the clinicians experience and patient outcomes. Our investment programme and strategy has focussed on solutions that rethink how clinicians will interact with the MAXIMS Platform by providing a more seamless and instinctive user experience. We have invested in enhancing the MAXIMS platform that will focus on harnessing data to drive operational and clinical efficiencies across healthcare settings.

We have invested heavily in developing an open ubiquitous interoperability platform that will empower clinicians by providing and harnessing a complete picture of the patient via seamless sharing of information across care settings. This ultimately delivers the foundations of an enterprise-wide approach to population health management. Our platform is now architected to always provide clinicians with a complete, accurate and trusted “Source of Truth” of their patients. By investing in the creation of an open, unified, scalable, and modular architecture it will enable our customers:

- Converting data to insights using an end-to-end ecosystem
- Open ecosystem, platform and architecture of interoperable apps, services and content
- Plug and play interoperability
- Open and unified clinical domain
- Enterprise-wide approach to population health-management
- Enabling personalized medicine
- Right Treatment to the right patient at the right time
- Enabling a learning health system
- Capacity and Patient Flow management
- Real-time and predictive analytics
- Care Coordination
- Actionable information and knowledge
- Collection of data from patients (Wearables, IoT, Patient Apps etc)

This strategic investment in our platform will accelerate our ambitions in the market and provide for several new opportunities:

- National, Regional, LHCRE and ICS wide solutions: Sharing live patient information within or across regions
- Population Health Management: Integrated care and systems that would deliver true personalised care. Ensuring the right care is given at the right time by the right person.
- Underpin the NHS Long Term Plan: Digitally enable ‘out of hospital’ care and enable the seamless flow of patient care data between health services
- Reduce pressures on staff and services: Enabling productive working, using technology to gain efficiencies in the delivery of services

**Integrated Medical Solutions Limited**


**Strategic report (continued)**  
**For the financial year ended 31 December 2019**

**Research and development (continued)**

- Enable patients access their healthcare records: Delivering person-centered care, promoting self-management and care
- Enables a learning health system: Agility to adapt to new ways of working, new care plans, redesign of services etc
- Supports continuous innovation and emerging technologies: without having to rip and replace legacy systems
- Vertical Integration

The Company is presently the major beneficiary of this investment programme, which is undertaken by its sister company in the group, Irish Medical Systems (Computers) Limited.

This report was approved by the board and signed on its behalf.

A rectangular box containing a handwritten signature in black ink. The signature appears to be "Brian P. Timmons" with a horizontal line extending to the right.

.....  
**Brian Timmons**  
Director

Date: 29 March 2021

## **Integrated Medical Solutions Limited**

# Directors' report

For the financial year ended 31 December 2019

The directors present their report and the financial statements for the financial year ended 31 December 2019.

### **Results and dividends**

The loss for the financial year, after taxation, amounted to £1,102,355 (2018 - loss £2,978,961).

There were no dividends recommended or paid to shareholders during the financial year (2018: £Nil)

### **Directors**

The directors who served during the year except as noted were as follows:

Brian Timmons

Shane Tickell (resigned 31 December 2019)

### **Going concern**

At 31 December 2019 the Company had net current liabilities of £9,609,360 (2018: £8,794,125) and at that date accumulated losses of £15,977,078 (2018: £14,874,723). The directors have prepared the financial statements on a going concern basis, the validity of which depends upon the continued financial support from Medical 2 Systems Limited. In this regard the company received confirmation that the required financial support will be forthcoming, which will enable the company to meet its debts as and when they fall due for a period of at least twelve months from the date of approval of these financial statements.

Having considered the foregoing, the directors believe it is appropriate to prepare the financial statements on a going concern basis.

### **COVID-19 Impact on operations**

Trading has been difficult from the end of the Quarter 1 2020, implementations have stalled as hospital staff have been deployed elsewhere to cope with the pandemic. This has caused a retrospective adjustment on our Wye Valley revenue recognition, impacting on our 2019 revenues.

Sales activity has slowed due to remote working and limited access to prospects, trade fairs have been cancelled and procurements have been delayed. All contact is now remote, and there has been difficulty following leads, for example GDPR issues in releasing home telephone numbers, all this results in fewer sales materialising from pipeline prospects. Fortunately, there has been a marked increase in sales and change requests to existing customers. It should also be noted that the changing market conditions due to the pandemic have affected our competitors also, opportunities have not been lost, just delayed, and new ones created.

Working from home has also posed issues, reliability of home internet, VPN connection issues, working in confined spaces not ergonomically designed to be used as workspaces, using laptop screens as opposed to two screens in the office, proximity of colleagues for fluidity of idea sharing. This has all lead to lower output and productivity.

The Company's customer support operations have held up well under COVID-19 pressures, and pre-pandemic business continuity planning has proven to work well and ensured that our healthcare customers continued to receive top quality support throughout this period.

Notwithstanding that the COVID-19 pandemic has had a negative impact on operations, the directors remain optimistic on the increased importance of integrated and interoperable healthcare software going into the future, It is felt that the inherent inadequacies in current systems and the stresses place thereon, will have been highlighted during the pandemic, for example Public Health England's use of spreadsheets to consolidate swab test results and the resulting loss of data. As the market opens up post pandemic, there will be multiple opportunities available for IMS to win.

**Integrated Medical Solutions Limited**

## Directors' report (continued)

For the financial year ended 31 December 2019

### **Events since the year end and future developments**

There have been no other significant events affecting the Company since the year end and the directors do not envisage any substantial change to the nature of the business in the foreseeable future.

### **Disclosure of information to auditor**


Each of the persons who are directors at the time when this Directors' report is approved has confirmed that:

- so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and
- the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

### **Auditor**

The auditor, Grant Thornton, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the board and signed on its behalf.



**Brian Timmons**  
Director

Date: 29 March 2021

## Directors' responsibilities statement

For the financial year ended 31 December 2019

The directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the Company's financial statements and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the board



.....  
**Brian Timmons**  
Director

Date: 29 March 2021



## Independent auditor's report to the members of Integrated Medical Solutions Limited

### **Opinion**

We have audited the financial statements of Integrated Medical Solutions Limited, which comprise the Statement of comprehensive income, the Balance sheet, the Statement of changes in equity for the financial year ended 31 December 2019, and the related notes to the financial statements, including a summary of significant accounting policies.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion, Integrated Medical Solutions Limited's financial statements:

- give a true and fair view in accordance with United Kingdom Generally Accepted Accounting Practice of the financial position of the Company as at 31 December 2019 and of its financial performance for the financial year then ended; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) ('ISAs') and applicable law. Our responsibilities under those standards are further described in the 'responsibilities of the auditor for the audit of the financial statements' section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, namely FRC's Ethical Standard concerning the integrity, objectivity and independence of the auditor. We have fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Conclusions relating to going concern**

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the Company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

## Independent auditor's report to the members of Integrated Medical Solutions Limited (continued)

### **Other information**

Other information comprises the information included in the Annual Report, other than the financial statements and our Auditor's report thereon, including the Directors' report and the Strategic Report. The directors are responsible for the other information. Our opinion on the financial statements does not cover the information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies in the financial statements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

### **Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

## Independent auditor's report to the members of Integrated Medical Solutions Limited (continued)

### **Responsibilities of management and those charged with governance for the financial statements**

Management is responsible for the preparation of the financial statements which give a true and fair view in accordance with United Kingdom Generally Accepted Accounting Practice, including FRS102 and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

### **Responsibilities of the auditor for the audit of the financial statements**

The objectives of an auditor are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK), the auditor will exercise professional judgment and maintain professional scepticism throughout the audit. They will also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for their opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

## Independent auditor's report to the members of Integrated Medical Solutions Limited (continued)


### **Responsibilities of the auditor for the audit of the financial statements (continued)**

- Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If they conclude that a material uncertainty exists, they are required to draw attention in the auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify their opinion. Their conclusions are based on the audit evidence obtained up to the date of the auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves a true and fair view.

The auditor shall communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that may be identified during the audit.

### **The purpose of our audit work and to whom we owe our responsibilities**

This report is made solely to the Company's members, as a body, in accordance with chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Stephen Murray (Senior statutory auditor)

for and on behalf of

**Grant Thornton**

Chartered Accountants

& Statutory Auditors

Dublin

Date: 29 March 2021

**Integrated Medical Solutions Limited**

**Statement of comprehensive income**

For the financial year ended 31 December 2019

	2019	2018
Note	£	£
Turnover	4,882,491	5,000,153
Cost of sales	(434,971)	(788,704)
<b>Gross profit</b>	<b>4,447,520</b>	<b>4,211,449</b>
Administrative expenses	(3,940,349)	(5,089,344)
Other operating charges	4 (849,896)	(995,707)
<b>Operating loss before depreciation &amp; amortisation - EBITDA</b>	<b>5 (342,725)</b>	<b>(1,873,602)</b>
Impairment of investment	-	(200,000)
Depreciation & amortisation	(740,336)	(786,234)
<b>Operating loss</b>	<b>5 (1,083,061)</b>	<b>(2,859,836)</b>
Interest payable	8 (19,194)	(119,125)
<b>Loss before tax</b>	<b>(1,102,255)</b>	<b>(2,978,961)</b>
Tax credit on loss	9 (100)	-
<b>Loss for the financial year</b>	<b>(1,102,355)</b>	<b>(2,978,961)</b>

There was no other comprehensive income for 2019 (2018: £NIL).


The notes on pages 16 to 30 form part of these financial statements.

**Integrated Medical Solutions Limited**  
**Registered number:03037895**

**Balance sheet**  
**As at 31 December 2019**

	Note	2019 £	2018 £
<b>Fixed assets</b>			
Intangible fixed assets	10	2,867,313	3,154,433
Investments	12	65,069	65,069
		<u>2,932,382</u>	<u>3,219,502</u>
<b>Current assets</b>			
Debtors: amounts falling due within one year	13	1,490,693	1,518,430
Cash at bank and in hand	15	270,631	420,759
		<u>1,761,324</u>	<u>1,939,189</u>
<b>Current liabilities</b>			
Creditors: amounts falling due within one year	16	(11,370,684)	(10,733,314)
		<u>(9,609,360)</u>	<u>(8,794,125)</u>
<b>Net current liabilities</b>		<u>(6,676,978)</u>	<u>(5,574,623)</u>
<b>Total assets less current liabilities</b>		<u>(6,676,978)</u>	<u>(5,574,623)</u>
<b>Net liabilities</b>		<u>(6,676,978)</u>	<u>(5,574,623)</u>
<b>Capital and reserves</b>			
Called up share capital	22	930,100	930,100
Share premium account	21	8,370,000	8,370,000
Profit and loss account	21	(15,977,078)	(14,874,723)
		<u>(6,676,978)</u>	<u>(5,574,623)</u>

The financial statements were approved and authorised for issue by the board and were signed on its behalf on



.....  
**Brian Timmons**  
 Director

Date: 29 March 2021

The notes on pages 16 to 30 form part of these financial statements.

**Integrated Medical Solutions Limited**

## Statement of changes in equity

For the financial year ended 31 December 2019

	Called up share capital	Share premium account	Profit and loss account	Total equity
	£	£	£	£
At 1 January 2019	930,100	8,370,000	(14,874,723)	(5,574,623)
<b>Comprehensive loss for the financial year</b>				
Loss for the financial year	-	-	(1,102,355)	(1,102,355)
<b>At 31 December 2019</b>	<b>930,100</b>	<b>8,370,000</b>	<b>(15,977,078)</b>	<b>(6,676,978)</b>

## Statement of changes in equity

For the financial year ended 31 December 2018

	Called up share capital	Share premium account	Profit and loss account	Total equity
	£	£	£	£
At 1 January 2018	930,100	8,370,000	(11,895,762)	(2,595,662)
<b>Comprehensive loss for the financial year</b>				
Loss for the financial year	-	-	(2,978,961)	(2,978,961)
<b>At 31 December 2018</b>	<b>930,100</b>	<b>8,370,000</b>	<b>(14,874,723)</b>	<b>(5,574,623)</b>

The notes on pages 16 to 30 form part of these financial statements.

## Notes to the financial statements

For the financial year ended 31 December 2019

### **1. Accounting policies**

#### **1.1 General information**

The company is a private company limited by shares and was incorporated in the United Kingdom and has a registered office at Saxon Court, 502 Avebury Boulevard, Milton Keynes, Buckinghamshire, MK9 3GD. The principal activity of the company during the year was developing and implementing high-quality healthcare information systems for the UK healthcare sector

#### **1.2 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with applicable accounting standards, including Financial Reporting Standard 102 - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' ('FRS 102'), and with the Companies Act 2006. The financial statements have been prepared on the historical cost basis except for the modification to a fair value basis for certain financial instruments as specified in the accounting policies below.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 2)

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- The requirements of section 7 Statement of Cash Flows;
- The requirements of section 3 Financial Statement Presentation paragraph 3.17(d);
- The requirements of section 11 Financial Instruments paragraphs 11.41(b), 11.41(c), 11.41(e), 11.41(f), 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
- The requirements of section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29 (b) and 12.29A; and
- The requirements of section 33 Related Party Transactions 33.7.

This information is included in the consolidated financial statements of Irish Medical Systems (Holdings) Limited, a company incorporated in Ireland, as at 31 December 2019, and these financial statements may be obtained from the Registrar of Companies in Ireland.

The following principal accounting policies have been applied:

#### **1.3 Turnover**

Turnover comprises the value (excluding value added tax and trade discounts) of goods sold and services rendered in the normal course of business. Turnover comprises software business, support and maintenance services and other products and services including hardware, training and project management services.

Turnover on long term contracts is recognised based on the percentage of total projects completed as at a given point in time. These percentages are based on agreed parameters as set initially by management and relate to the stage of completion of the project. This ensures that revenues and costs are evenly matched and that profits, if any, taken to the Statement of Comprehensive Income at the end of the accounting period reflect the proportion of the project completed at that date.

## Notes to the financial statements

For the financial year ended 31 December 2019

### 1. Accounting policies (continued)

#### 1.3 Turnover (continued)

Support and maintenance services revenue is recognised evenly on a straight line basis over the period of the contract.

In the case where separable revenue items are contractually tied to implementation, then said revenue is recognised over the period of implementation once a contract has commenced to ensure that revenue and costs are appropriately aligned.

#### 1.4 Research and development

Research expenditure is written off in the year in which it is incurred. Development expenditure incurred on clearly defined projects whose outcome can be assessed with reasonable certainty is carried forward and amortisation is charged from that time over the lesser of the life of the project or ten years.

#### 1.5 Going concern

At 31 December 2019 the Company had net current liabilities of £9,609,360 (2018: £8,794,125) and at that date accumulated losses of £15,977,078 (2018: £14,874,723). The directors have prepared the financial statements on a going concern basis, the validity of which depends upon the continued financial support from Irish Medical Systems (Holdings) Limited. In this regard the company received confirmation that the required financial support will be forthcoming, which will enable the company to meet its debts as and when they fall due for a period of at least twelve months from the date of approval of these financial statements.

Having considered the foregoing, the directors believe it is appropriate to prepare the financial statements on a going concern basis.

#### 1.6 Other intangibles and amortisation

Expenditure incurred on intangible assets is capitalised and amortised over the anticipated useful economic life. The carrying amount is reviewed at each balance sheet date to determine whether there is any indication of impairment. In assessing assets for impairment, the assets recoverable amount is estimated. An impairment loss is recognised when the carrying amount of an asset exceeds its recoverable amount.

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Development expenditure	10% straight line
Website	20% straight line

#### 1.7 Fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the costs of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Long-term leasehold property	25% straight line
Fixtures and fittings	25% straight line
Computer equipment	25% straight line

## Notes to the financial statements

For the financial year ended 31 December 2019

### 1. Accounting policies (continued)

#### 1.7 Fixed assets and depreciation (continued)

The carrying amount of the depreciable assets, other than deferred tax assets, are reviewed at each balance sheet date to determine whether there is any indication of impairment. Non depreciable assets are assessed annually for impairment. In assessing assets for impairment, the assets recoverable amount is estimated. An impairment loss is recognised when the carrying amount of an asset exceeds its recoverable amount.

#### 1.8 Operating lease agreements

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged against profits on a straight line basis over the period of the lease.

#### 1.9 Pension costs

The company operates a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the company. The annual contributions payable are charged to the profit and loss account.

#### 1.10 Deferred taxation

Full provision is made for deferred tax assets and liabilities arising from all timing differences between the recognition of gains and losses in the financial statements and recognition in the tax computation.

A net deferred tax asset is recognised only if it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

Deferred tax assets and liabilities are calculated at the tax rates expected to be effective at the time the timing differences are expected to reverse.

Deferred tax assets and liabilities are not discounted.

#### 1.11 Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

#### 1.12 Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment. Where merger relief is applicable, the cost of the investment in a subsidiary undertaking is measured at the nominal value of the shares issued together with the fair value of any additional consideration paid.

#### 1.13 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, including transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

## Notes to the financial statements

For the financial year ended 31 December 2019

### 1. Accounting policies (continued)

#### 1.14 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

#### 1.15 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, including transaction costs, and are measured subsequently at amortised cost using the effective interest method.

#### 1.16 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the case of a small company, or a public benefit entity concessionary loan.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

## Notes to the financial statements

For the financial year ended 31 December 2019

### 2. Judgments in applying accounting policies and key sources of estimation uncertainty

When preparing the financial statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses.

The following are significant management judgements in applying the accounting policies of the company that have the most significant effect on the financial statements.

#### *Capitalisation of internally developed software*

Distinguishing the research and development phases of a new customised software project and determining whether the recognition requirements for the capitalisation of development costs are met requires judgement. After capitalisation, management monitors whether the recognition requirements continue to be met and whether there are any indicators that capitalised costs may be impaired.

#### *Recognition of deferred tax assets*

The extent to which deferred tax assets can be recognised is based on an assessment of the probability of the company's future taxable income against which the deferred tax assets can be utilised. In addition, significant judgement is required in assessing the impact of any legal or economic limits or uncertainties in various tax jurisdictions.

#### *Fixed asset investments*

Management must determine whether there are indicators of impairment of the company's carrying value of investments in subsidiary companies. Factors taken into consideration in reaching such a decision include the economic viability and expected future financial performance of the subsidiaries and their current net asset values.

### Estimation uncertainty

Information about estimates and assumptions that have the most significant effect on recognition and measurement of assets, liabilities, income and expenses is provided below. Actual results may be substantially different.

#### *Revenue recognition*

Management apply a robust methodology in determining the appropriate revenue recognition pattern on a contract by contract basis.

#### *Impairment*

In assessing impairment, management estimates the recoverable amount of each asset or cash-generating units based on expected future cash flows and uses an interest rate to discount them. Estimation uncertainty relates to assumptions about future operating results and the determination of a suitable discount rate.

#### *Useful lives of depreciable assets*

Management reviews its estimate of the useful lives of depreciable assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical and physical obsolescence that may change the utility of certain property, plant and equipment.

**Integrated Medical Solutions Limited**

## Notes to the financial statements

For the financial year ended 31 December 2019

### 3. Turnover

Analysis of turnover by class of business is as follows:

	2019 £	2018 £
Services, implementation & training	2,283,411	2,134,440
Maintenance	2,233,642	2,346,799
Other income	365,438	518,914
	<u>4,882,491</u>	<u>5,000,153</u>

All turnover arose within the United Kingdom.

### 4. Other operating charges

	2019 £	2018 £
Royalty charge	<u>(849,896)</u>	<u>(995,707)</u>

### 5. Operating loss

The operating loss is stated after charging:

	2019 £	2018 £
Depreciation of tangible fixed assets	-	10,458
Amortisation of intangible assets	740,336	775,776
Impairment of fixed asset investment	-	200,000
Exchange differences	(355,098)	78,755
Operating lease rentals	179,398	148,431
Defined contribution pension cost	<u>134,014</u>	<u>174,384</u>

## Integrated Medical Solutions Limited

# Notes to the financial statements

For the financial year ended 31 December 2019

### 6. Employees

Staff costs, including directors' remuneration, were as follows:

	2019	2018
	£	£
Wages and salaries	2,473,695	3,204,378
Social security costs	304,697	410,297
Cost of defined contribution scheme	155,101	174,384
	<u>2,933,493</u>	<u>3,789,059</u>

Total wages, salaries and pension costs capitalised as development costs during the year amounted to £453,216 (2018: £577,624).

The average monthly number of employees, including the directors, during the financial year was as follows:

	2019	2018
	No.	No.
Central	8	10
Platform	6	7
Support	6	6
Implementation	15	18
Sales	7	11
Technical services	5	7
	<u>47</u>	<u>59</u>

### 7. Directors' remuneration

	2019	2018
	£	£
Directors' emoluments	210,238	510,319
Company contributions to defined contribution pension schemes	29,140	26,524
	<u>239,378</u>	<u>536,843</u>

At year end retirement benefits were accruing to directors of £NIL (2018 - £1,337) in respect of defined contribution pension schemes. The highest paid director received remuneration of £110,000 (2018 - £144,075). Pension contributions relating to the highest paid director amounted to £NIL (2018: £9,973).

**Integrated Medical Solutions Limited**

**Notes to the financial statements**

For the financial year ended 31 December 2019

**8. Interest payable and similar expenses**

	2019	2018
	£	£
Bank interest payable	<u>19,194</u>	<u>119,125</u>

**9. Taxation**

	2019	2018
	£	£
Corporation tax		
Current tax credit on loss for the year	<u>100</u>	-
<b>Total current tax</b>	<u>100</u>	-
<b>Taxation on loss on ordinary activities</b>	<u>100</u>	-

**Factors affecting tax charge for the year**

The tax assessed for the financial year is higher than (2018 - higher than) the standard rate of corporation tax in the UK of 19% (2018 - 19%). The differences are explained below:

	2019	2018
	£	£
Loss on ordinary activities before tax	<u>(1,102,255)</u>	<u>(2,978,961)</u>
Loss on ordinary activities multiplied by standard rate of corporation tax in the UK of 19% (2017 -19.25%)	(209,428)	(566,003)
<b>Effects of:</b>		
Expenses not deductible for tax purposes	37,968	147,397
Unrelieved tax losses carried forward	<u>171,560</u>	<u>418,606</u>
<b>Total tax charge for the financial year</b>	<u>100</u>	-

**Integrated Medical Solutions Limited**

**Notes to the financial statements**

For the financial year ended 31 December 2019

**10. Intangible assets**

	Development expenditure £
<b>Cost</b>	
At 1 January 2019	9,827,597
Additions - internal	453,216
At 31 December 2019	<u>10,280,813</u>
<b>Amortisation</b>	
At 1 January 2019	6,673,164
Charge for the year	740,336
At 31 December 2019	<u>7,413,500</u>
<b>Net book value</b>	
At 31 December 2019	<u>2,867,313</u>
At 31 December 2018	<u>3,154,433</u>

The directors are satisfied that the carrying value of intangible assets are not stated in excess of their recoverable amount.

**Integrated Medical Solutions Limited**

## Notes to the financial statements

For the financial year ended 31 December 2019

### 11. Tangible fixed assets

	Freehold property £	Fixtures and fittings £	Computer equipment £	Total £
<b>Cost or valuation</b>				
At 1 January 2019	15,000	27,263	113,090	155,353
At 31 December 2019	15,000	27,263	113,090	155,353
<b>Depreciation</b>				
At 1 January 2019	15,000	27,263	113,090	155,353
At 31 December 2019	15,000	27,263	113,090	155,353
<b>Net book value</b>				
At 31 December 2019	-	-	-	-
At 31 December 2018	-	-	-	-

**Integrated Medical Solutions Limited**

## Notes to the financial statements

For the financial year ended 31 December 2019

### 12. Fixed asset investments

	Investments in subsidiary companies £
<b>Cost or valuation</b>	
At 1 January 2019	265,069
At 31 December 2019	<u>265,069</u>
<b>Impairment</b>	
At 1 January 2019	200,000
At 31 December 2019	<u>200,000</u>
<b>Net book value</b>	
At 31 December 2019	<u>65,069</u>
At 31 December 2018	<u>65,069</u>

At 1 January 2019 and 31 December 2019, the company held investments in the ordinary shares and voting rights of two companies registered in the United Kingdom; Preview Health Limited and Beronbrook Limited. Both companies are involved in the marketing and development of software systems for the healthcare industry. The registered office of both companies is at Saxon Court Offices, 502 Avebury Boulevard, Central Milton Keynes, MK9 3GD.

Under S400 of the Companies Act 2006 the company is exempt from the requirement to prepare consolidated financial statements on the basis that they are included within the consolidated accounts of the immediate parent undertaking Irish Medical Systems (Holdings) Limited. Consequently, these financial statements deal with the results of the company as a single entity.

The directors have considered the carrying values of these investments and recognised an impairment of £Nil in 2019 (2018: £200,000).

#### Subsidiary undertakings

The following were subsidiary undertakings of the Company:

Name	Class of shares	Holding	Principal activity
Beronbrook Limited	Ordinary	100	Dormant company
Preview Health Limited	Ordinary	100	Dormant company

## Notes to the financial statements

For the financial year ended 31 December 2019

### 12. Fixed asset investments (continued)

#### Subsidiary undertakings (continued)

The aggregate of the share capital and reserves as at 31 December 2019 and the profit or loss for the financial year ended on that date for the subsidiary undertakings were as follows:

Name	Aggregate of share capital and reserves £	Profit/(Loss) £
Beronbrook Limited	-	-
Preview Health Limited	1	1

### 13. Debtors: Amounts falling due within one year

	2019 £	2018 £
Trade debtors	226,892	276,302
Other debtors	239	992
Prepayments	51,698	228,843
Accrued income	332,761	133,190
Deferred taxation	879,103	879,103
	<u>1,490,693</u>	<u>1,518,430</u>

An impairment loss of £NIL (2018: £NIL) is recognised against trade debtors.

### 14. Deferred taxation

	2019 £	2018 £
At beginning of year	879,103	879,103
At end of year	<u>879,103</u>	<u>879,103</u>

**Integrated Medical Solutions Limited**

## Notes to the financial statements

For the financial year ended 31 December 2019

### 14. Deferred taxation (continued)

The deferred tax asset is made up as follows:

	2019	2018
	£	£
Tax losses carried forward	<u>879,103</u>	<u>879,103</u>

### 15. Cash and cash equivalents

	2019	2018
	£	£
Cash at bank and in hand	<u>270,631</u>	<u>420,759</u>

### 16. Creditors: Amounts falling due within one year

	2019	2018
	£	£
Trade creditors	366,263	318,771
Amounts owed to group undertakings	9,660,352	8,568,900
Other taxation and social security	230,179	197,280
Other creditors	2,070	56,383
Accruals	137,882	141,117
Deferred income	973,938	1,450,863
	<u>11,370,684</u>	<u>10,733,314</u>

Trade and other creditors are payable at various dates over the coming months in accordance with the suppliers' usual and customary credit terms.

The amounts owed to group undertakings are unsecured, interest free and have no fixed repayment terms.

All taxes including social insurance are repayable at various dates over the coming months in accordance with the applicable statutory provisions.

### 17. Loan security

A floating charge was registered against all property of the company in favour of a third party lender for the purpose of securing the loan granted to Irish Medical Systems (Computers) Limited, a wholly owned company of Irish Medical Systems (Holding) Limited (Parent company).

## Notes to the financial statements

For the financial year ended 31 December 2019

### 18. Pension commitments

The company operates a defined contribution scheme for its employees. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension charge for the year was £155,101 (2018: £174,384). An element of the pension charge has been capitalised as part of development costs. The unpaid contribution outstanding at the year-end included in accruals is £28,906 (2018: £37,618).

### 19. Commitments under operating leases

At 31 December 2019 the Company had future minimum lease payments under non-cancellable operating leases as follows:

	2019 £	2018 £
Not later than 1 year	<u>93,250</u>	<u>49,000</u>

### 20. Related party transactions

The company has availed of the exemption provided in FRS 102, Section 33, "Related Party Disclosures" not to disclose transactions entered into with fellow group companies that are wholly owned within the group of companies of which the company is a wholly owned member.

### 21. Reserves

#### Share premium account

Share premium account includes any premiums received on issue of share capital. Any transaction costs associated with the issuing of shares are deducted from share premium. There was no movement on the share premium account during the year 2019: £8,370,000 (2018: £8,370,000).

#### Profit and loss account

The profit and loss account includes all current and prior periods retained profits and losses. The accumulated losses at 31 December 2019 were (£15,977,078) (2018: (£14,874,723)).

### 22. Share capital

	2019 £	2018 £
<b>Authorised</b>		
1,000,000 (2018 - 1,000,000) Ordinary shares of £1.00 each	<u>1,000,000</u>	<u>1,000,000</u>
<b>Allotted, called up and fully paid</b>		
930,100 (2018 - 930,100) Ordinary shares of £1.00 each	<u>930,100</u>	<u>930,100</u>

## Notes to the financial statements

For the financial year ended 31 December 2019

### **23. Post balance sheet events**

On 11 of March 2020, the World Health Organisation officially declared COVID-19, the disease caused by novel coronavirus, a pandemic.

Trading has been difficult from the end of the Quarter 1 2020, implementations have stalled as hospital staff have been deployed elsewhere to cope with the pandemic. This has caused a retrospective adjustment on our Wye Valley revenue recognition, impacting on our 2019 revenues.

Sales activity has slowed due to remote working and limited access to prospects, trade fairs have been cancelled and procurements have been delayed. All contact is now remote, and there has been difficulty following leads, for example GDPR issues in releasing home telephone numbers, all this results in fewer sales materialising from pipeline prospects. Fortunately, there has been a marked increase in sales and change requests to existing customers. It should also be noted that the changing market conditions due to the pandemic have affected our competitors also, opportunities have not been lost, just delayed, and new ones created.

Working from home has also posed issues, reliability of home internet, VPN connection issues, working in confined spaces not ergonomically designed to be used as workspaces, using laptop screens as opposed to two screens in the office, proximity of colleagues for fluidity of idea sharing. This has all lead to lower output and productivity.

The Company's customer support operations have held up well under COVID-19 pressures, and pre-pandemic business continuity planning has proven to work well and ensured that our healthcare customers continued to receive top quality support throughout this period.

Notwithstanding that the COVID-19 pandemic has had a negative impact on operations, the directors remain optimistic on the increased importance of integrated and interoperable healthcare software going into the future, It is felt that the inherent inadequacies in current systems and the stresses place thereon, will have been highlighted during the pandemic, for example Public Health England's use of spreadsheets to consolidate swab test results and the resulting loss of data. As the market opens up post pandemic, there will be multiple opportunities available for IMS to win.

### **24. Controlling party**

The immediate parent undertaking is Irish Medical Systems (Holdings) Limited a company incorporated in the Republic of Ireland with its registered office and Irish Lights Building, Harbour Road, Dun Laoghaire, Co. Dublin. The ultimate parent undertaking is Medical 2 Systems Limited, a company incorporated in the Isle of Man with its registered office at Fort Anne, Douglas, Isle of Man, IM1 5PD.

The smallest and largest group into which the results of Integrated Medical Solutions Limited are incorporated is that headed up by Irish Medical Systems (Holdings) Limited, a company incorporated in the Republic of Ireland with its registered office at Irish Lights Building, Harbour Road, Dun Laoghaire, Co. Dublin. Group financial statements of Irish Medical Systems (Holdings) Limited are filed with the Companies Registration Office.

### **25. Approval of financial statements**

The board of directors approved these financial statements for issue on 29 March 2021 .